Quant'AbondanceL'abondance, quantifiée.

Actualités

Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.

23,580 signal articles · 332 in last 24h · 112,379 total before filter · latest 40m ago
332last 24h
2138last 7d
376● bullish (7d)
188● bearish (7d)
204publishers
AllMacro294Earnings1216M&A91Regulatory23Product13Analyst20
✕ clear all filtersticker: PMSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Philip Morris International Q2 Earnings Call Highlights
MarketBeat21d agoneutral
Philip Morris International Q2 Earnings Call Highlights

Philip Morris International (NYSE:PM) reported what management described as a “very strong” second quarter, with growth led by its international smoke-free products business and a better-than-expected performance in combustibles. Emmanuel Babeau, the company’s group chief financial officer, said Ph

How To Earn $500 A Month From Philip Morris Stock Ahead Of Q2 Earnings
Benzinga21d agoneutral
How To Earn $500 A Month From Philip Morris Stock Ahead Of Q2 Earnings

Philip Morris International Inc‘s (NYSE:PM) investors may be eyeing potential gains from the tobacco company’s dividends ahead of its second-quarter earnings report on Wednesday, July 22. Analysts expect quarterly earnings of $2.05 per share, up from $1.91 per share in...

Philip Morris Shares Ease After Company Trims 2026 Earnings Outlook (PM)
InvestorsHub71d agoneutral
Philip Morris Shares Ease After Company Trims 2026 Earnings Outlook (PM)

Philip Morris International (NYSE:PM) shares edged lower in premarket trading on Tuesday after the tobacco group reduced its full-year adjusted earnings guidance, reflecting the impact of an expected impairment charge and currency-related headwinds. The stock slipped around 1% before the opening bell as investors assessed the updated outlook.

FDA Guidance Lifts Philip Morris Smoke Free Story And Valuation Debate
Simply Wall St.88d agoneutral
FDA Guidance Lifts Philip Morris Smoke Free Story And Valuation Debate

FDA issues new regulatory guidance that supports commercialization of Philip Morris International's ZYN Ultra and IQOS in the U.S. The agency indicates it will not prioritize enforcement against nicotine pouch and e-vapor products with accepted premarket tobacco applications. This update reduces regulatory uncertainty around NYSE:PM smoke free products and is reflected in stronger Q1 results and improved sentiment among market participants. For investors watching NYSE:PM, this FDA shift...